Proto Oncogene Proteins C Pim 1 Inhibitors Pipeline Insight

DelveInsight’s, “Proto Oncogene Proteins C PIM 1 Inhibitors – Pipeline Insight, 2022,” report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Proto Oncogene Proteins C PIM 1 Inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. 

Geography Covered

  • Global coverage

Proto Oncogene Proteins C PIM 1 Inhibitors Understanding

Proto Oncogene Proteins C PIM 1 Inhibitors: Overview

PIM (proviral integration site for moloney murine leukemia virus) kinase plays a key role as an oncogene in various cancers including myeloma, leukemia, prostate and breast cancers. The PIM kinases, which constitute a class of serine/threonine kinase, act as oncoproteins and promote cell survival by transcriptional activation of genes involved in cell proliferation. The family of PIM kinase consists of three isoforms, PIM-1, PIM-2, and PIM-3. Each of the PIM kinases plays an important role in tumorigenesis. While PIM-1 has been reported to be over-expressed in several hematological and solid tumors PIM-2 is highly expressed in myeloma, lymphoma and leukemia. The elevated expression of PIM-3 has been noted in adeno-carcinomas. Diverse roles that the PIM kinases play in carcinogenesis include multiple myeloma proliferation, anti- apoptosis, cell cycle modulation, and mediating bone destruction. PIM kinases have been well studied as a potential therapeutic target for developing anti-cancer drugs due to their pivotal roles in cancers.

 

"Proto Oncogene Proteins C PIM 1 Inhibitors - Pipeline Insight, 2022" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Proto Oncogene Proteins C PIM 1 Inhibitors pipeline landscape is provided which includes the disease overview and Proto Oncogene Proteins C PIM 1 Inhibitors treatment guidelines. The assessment part of the report embraces, in depth Proto Oncogene Proteins C PIM 1 Inhibitors commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Proto Oncogene Proteins C PIM 1 Inhibitors collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Proto Oncogene Proteins C PIM 1 Inhibitors R&D. The therapies under development are focused on novel approaches to treat/improve Proto Oncogene Proteins C PIM 1 Inhibitors.

Proto Oncogene Proteins C PIM 1 Inhibitors Emerging Drugs Chapters

This segment of the Proto Oncogene Proteins C PIM 1 Inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

 

Proto Oncogene Proteins C PIM 1 Inhibitors Emerging Drugs

 

MEN 1703: Menarini Group

MEN1703 is a dual kinase inhibitor targeting PIM (PIM1, PIM2, and PIM 3) and FLT3 kinases. FLT3 internal tandem duplication (FLT3-ITD) is one of the most common genetic lesions in acute myeloid leukemia patients (AML) and is associated with a poor prognosis. PIM kinases are thought to be one of the major drivers of the resistance phenotype to FLT3 inhibitors and their inhibition in relapsed samples restores cell sensitivity to FLT3 inhibitors these agents. The spectrum of activity of MEN1703 also warrants the compound investigation in AML patients regardless of FLT3 aberrations. MEN1703 is being investigated as potential treatment for adult patients with relapsed/refractory AML in Phase II clinical trial.

Further product details are provided in the report……..

Proto Oncogene Proteins C PIM 1 Inhibitors: Therapeutic Assessment

This segment of the report provides insights about the different Proto Oncogene Proteins C PIM 1 Inhibitors drugs segregated based on following parameters that define the scope of the report, such as:

  • Major Players in Proto Oncogene Proteins C PIM 1 Inhibitors

There are approx. 5+ key companies which are developing the therapies for Proto Oncogene Proteins C PIM 1 Inhibitors. The companies which have their Proto Oncogene Proteins C PIM 1 Inhibitors drug candidates in the most advanced stage, i.e. phase II include Menarini Group.

Phases

DelveInsight’s report covers around 5+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

 

Proto Oncogene Proteins C PIM 1 Inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Subcutaneous
  • Intravenous
  • Intramuscular
  • Molecule Type

 

Products have been categorized under various Molecule types such as

  • Peptides
  • Polymer
  • Small molecule
  • Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Proto Oncogene Proteins C PIM 1 Inhibitors: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Proto Oncogene Proteins C PIM 1 Inhibitors therapeutic drugs key players involved in developing key drugs.

 

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Proto Oncogene Proteins C PIM 1 Inhibitors drugs.

Proto Oncogene Proteins C PIM 1 Inhibitors Report Insights

  • Proto Oncogene Proteins C PIM 1 Inhibitors Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs

Proto Oncogene Proteins C PIM 1 Inhibitors Report Assessment

  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

  • How many companies are developing Proto Oncogene Proteins C PIM 1 Inhibitors drugs?
  • How many Proto Oncogene Proteins C PIM 1 Inhibitors drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Proto Oncogene Proteins C PIM 1 Inhibitors?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Proto Oncogene Proteins C PIM 1 Inhibitors therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Proto Oncogene Proteins C PIM 1 Inhibitors and their status?
  • What are the key designations that have been granted to the emerging drugs?

Introduction

Executive Summary

Proto Oncogene Proteins C PIM 1 Inhibitors: Overview

  • Causes
  • Mechanism of Action
  • Signs and Symptoms
  • Diagnosis
  • Disease Management

Pipeline Therapeutics

  • Comparative Analysis

Therapeutic Assessment

  • Assessment by Product Type
  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type

Mid Stage Products (Phase II)

  • Comparative Analysis

MEN 1703: Menarini Group

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Early Stage Products (Phase I/II)

  • Comparative Analysis

Uzansertib: Incyte Corporation

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Inactive Products

  • Comparative Analysis

Proto Oncogene Proteins C PIM 1 Inhibitors Key Companies

Proto Oncogene Proteins C PIM 1 Inhibitors Key Products

Proto Oncogene Proteins C PIM 1 Inhibitors- Unmet Needs

Proto Oncogene Proteins C PIM 1 Inhibitors- Market Drivers and Barriers

Proto Oncogene Proteins C PIM 1 Inhibitors- Future Perspectives and Conclusion

Proto Oncogene Proteins C PIM 1 Inhibitors Analyst Views

Proto Oncogene Proteins C PIM 1 Inhibitors Key Companies

Appendix

List of Table

Table 1: Total Products for Proto Oncogene Proteins C PIM 1 Inhibitors

Table 2: Late Stage Products

Table 3: Mid Stage Products

Table 4: Early Stage Products

Table 5: Pre-clinical & Discovery Stage Products

Table 6: Assessment by Product Type

Table 7: Assessment by Stage and Product Type

Table 8: Assessment by Route of Administration

Table 9: Assessment by Stage and Route of Administration

Table 10: Assessment by Molecule Type

Table 11: Assessment by Stage and Molecule Type

Table 12: Inactive Products

List of Figures

Figure 1: Total Products for Proto Oncogene Proteins C PIM 1 Inhibitors

Figure 2: Late Stage Products                             

Figure 3: Mid Stage Products

Figure 4: Early Stage Products

Figure 5: Preclinical and Discovery Stage Products

Figure 6: Assessment by Product Type                                                                       

Figure 7: Assessment by Stage and Product Type

Figure 8: Assessment by Route of Administration

Figure 9: Assessment by Stage and Route of Administration

Figure 10: Assessment by Molecule Type

Figure 11: Assessment by Stage and Molecule Type

Figure 12: Inactive Products

• Tolero Pharmaceuticals
• Novartis
• Inflection Biosciences/AUM Biosciences
• Menarini
• Incyte Corporation
• AstraZeneca

 

Forward to Friend

Need A Quote